Louiza Labs Wants to Be Hebbia for Pharma, and Regulators Might Actually Love It

The Macro: The Drug Got Approved, Now the Real Fight Begins

Most people think the hard part of bringing a drug to market is getting FDA approval. That is the dramatic part, sure. Years of clinical trials, billions in R&D, binary yes-or-no moments that determine whether a company survives. But there is a less glamorous battle that happens after approval, and it is just as consequential: convincing payors to actually cover the drug.

Insurance companies, Medicare, Medicaid, pharmacy benefit managers. They all want evidence. Not just the clinical trial data that got the drug approved, but real-world evidence that it works for specific patient populations, in specific clinical settings, compared to specific alternatives. The teams responsible for assembling this evidence are called Health Economics and Outcomes Research (HEOR) and Market Access teams, and they are perpetually overwhelmed.

The problem is that pharmaceutical evidence is scattered across thousands of sources. Clinical trial databases, real-world claims data, electronic health records, published literature, conference abstracts, regulatory submissions from other countries. A single evidence synthesis project can involve reviewing hundreds of studies, extracting data points from each one, assessing quality and bias, and weaving it all into a narrative that satisfies both scientific rigor and commercial objectives.

This work is done manually. Teams of PhDs and medical writers spend weeks or months on a single dossier. The tools they use are general purpose. Think Excel, Covidence, and a lot of copy-pasting between PDFs and Word documents. The market for this kind of evidence synthesis and regulatory intelligence is massive, but the tooling is stuck in 2010.

Hebbia raised $130 million to bring AI to knowledge work broadly. Atropos Health is applying AI to real-world evidence generation. But neither is purpose-built for the specific workflow of pharmaceutical market access: the intersection of regulatory compliance, clinical evidence synthesis, and payor negotiation.

The Micro: An Apple Engineer and a Harvard Medical Researcher Walk Into a Pharma Problem

Larissa Tyagi founded Louiza Labs after a career that looks like someone was deliberately collecting credentials for this exact company. She was a software engineer at Apple and studied at Carnegie Mellon. The broader team brings experience from NVIDIA’s AI division, large-cap pharma clinical trial launches, and Harvard Medical School training. It is a small team of two, based in San Francisco, backed by Y Combinator (Summer 2025) with Gustaf Alstromer as their primary partner.

The product synthesizes fragmented pharmaceutical and medical device data to accomplish three things: prove safety, optimize market access, and anticipate regulatory response. The “auditable” part is critical. In regulated industries, you cannot just hand a regulator an AI-generated summary and expect them to accept it. Every claim needs to trace back to its source. Every data point needs provenance. The AI has to show its work.

Louiza Labs is building that traceability into the core product. When the system synthesizes evidence from fifty studies, you can click on any conclusion and see exactly which studies support it, what the quality scores are, and where the original data lives. This is not a nice-to-have feature. It is a regulatory requirement.

The 10x speed claim is about the end-to-end workflow. What currently takes a team of specialists several weeks, Louiza Labs compresses into days. Not by cutting corners, but by automating the extraction, synthesis, and formatting steps that consume most of the analyst’s time. The human expert still reviews and validates the output, but they are reviewing a completed draft rather than building one from scratch.

The competitive positioning as “Hebbia for pharmaceutical evidence” is useful shorthand but also undersells the specialization involved. Hebbia is a general-purpose AI knowledge platform. Louiza Labs is building domain-specific models that understand pharmaceutical regulatory frameworks, clinical trial design, and payor decision criteria. That specialization is what makes the output useful rather than merely fast.

The pharma market access workflow is the kind of niche that looks small from the outside but is actually enormous. Every drug that gets approved needs this work done. Every medical device, every biologic, every biosimilar. The market is global, the work is recurring, and the customers are some of the wealthiest companies on earth.

The Verdict

I am bullish on the thesis. Pharma market access is a workflow that is expensive, manual, high-stakes, and ripe for AI. The regulatory requirement for auditability is actually a moat, because it means you cannot just throw a general-purpose LLM at the problem and call it a day. You need purpose-built infrastructure that maintains provenance, and that is hard to replicate.

The risk is the classic two-person startup problem: can they build fast enough to establish a position before a larger company decides to move into this space? Veeva Systems already owns the pharma CRM and clinical trial market. If Veeva decides to add AI-powered evidence synthesis to its platform, Louiza Labs would be competing against a company with 40,000 pharma customers and $2.4 billion in annual revenue.

Thirty days, I want to see pilot customers from actual pharma HEOR teams using the product on real dossiers. Sixty days, I want to know whether the auditability features actually satisfy regulatory reviewers, not just internal teams. Ninety days, the question is whether Louiza Labs can demonstrate that its output quality matches or exceeds what a team of PhDs produces manually. If the quality holds, the speed advantage makes this an obvious buy. If the quality falls short, no amount of speed matters in a regulated industry.